Immunome Inc. is a biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies, specializing in antibody-drug conjugates (ADCs) and other oncology therapeutics. Its pipeline includes varegacestat (a Phase 3 gamma secretase inhibitor for desmoid tumors), IM-1021 (a ROR1 ADC in Phase 1), IM-3050 (a FAP-targeted radioligand therapy with IND clearance), and three preclinical solid tumor ADCs (IM-1617, IM-1340, IM-1335).
expected 2026-11-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-088172 | EDGAR | 90K words |
| 2025-03-19 | 2024-12-31 | 0001558370-25-003302 | EDGAR | 44K words |
| 2024-03-28 | 2023-12-31 | 0001558370-24-004247 | EDGAR | 94K words |
| 2023-03-16 | 2022-12-31 | 0001558370-23-003964 | EDGAR | 75K words |
| 2022-03-28 | 2021-12-31 | 0001558370-22-004420 | EDGAR | 71K words |
| 2021-03-25 | 2020-12-31 | 0001558370-21-003493 | EDGAR | 84K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-09 | 2026-09-30 | 0001193125-26-453597 | EDGAR | 61K words |
| 2026-08-11 | 2026-06-30 | 0001193125-26-344636 | EDGAR | 59K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269603 | EDGAR | 60K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104035 | EDGAR | 60K words |
| 2025-05-12 | 2025-03-31 | 0001558370-25-007382 | EDGAR | 58K words |
| 2024-11-13 | 2024-09-30 | 0001558370-24-015524 | EDGAR | 61K words |
| 2024-08-12 | 2024-06-30 | 0001558370-24-011898 | EDGAR | 60K words |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008066 | EDGAR | 58K words |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018425 | EDGAR | 59K words |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014090 | EDGAR | 22K words |
| 2023-05-05 | 2023-03-31 | 0001558370-23-008194 | EDGAR | 18K words |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017574 | EDGAR | 19K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-09 | 0001193125-26-453556 | EDGAR | 2K words |
| 2026-10-05 | 0001193125-26-413217 | EDGAR | 12K words |
| 2026-08-11 | 0001193125-26-344577 | EDGAR | 2K words |
| 2026-03-03 | 0001193125-26-088141 | EDGAR | 2K words |
| 2025-12-17 | 0001193125-25-322877 | EDGAR | 1K words |
| 2025-12-15 | 0001193125-25-318429 | EDGAR | 3K words |
| 2025-11-06 | 0001193125-25-269538 | EDGAR | 2K words |
| 2025-08-06 | 0000950170-25-104015 | EDGAR | 2K words |
| 2025-06-11 | 0001104659-25-058523 | EDGAR | 1K words |
| 2025-05-12 | 0001104659-25-047304 | EDGAR | 2K words |
126 total filings indexed. 98 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001472012 |
| Ticker | IMNM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.immunome.com |
| Listed | 2020-10-02 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/IMNM (~200 tokens, structured JSON with cryptographic provenance)